An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia

Nature Medicine

Volumn 21, Issue 5, 2015, Pages 492-497

  Sehgal, Alfica ^a   Barros, Scott ^a   Ivanciu, Lacramioara ^b   Cooley, Brian ^c   Qin, June ^a   Racie, Tim ^a   Hettinger, Julia ^a   Carioto, Mary ^a   Jiang, Yongfeng ^a   Brodsky, Josh ^a   Prabhala, Harsha ^a   Zhang, Xuemei ^a   Attarwala, Husain ^a   Hutabarat, Renta ^a   Foster, Don ^a   Milstein, Stuart ^a   Charisse, Klaus ^a   Kuchimanchi, Satya ^a   Maier, Martin A ^a   Nechev, Lubo ^a   Kandasamy, Pachamuthu ^a   Kel'In, Alexander V ^a   Nair, Jayaprakash K ^a   Rajeev, Kallanthottathil G ^a   Manoharan, Muthiah ^a   Meyers, Rachel ^a   Sorensen, Benny ^a   Simon, Amy R ^a   Dargaud, Yesim ^d   Negrier, Claude ^d   Camire, Rodney M ^b   Akinc, Akin ^a   more..

^a ALNYLAM PHARMACEUTICALS   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ANIMAL; BLOOD CLOTTING; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENETICS; HEMOPHILIA A; HEMOSTASIS; HOMOZYGOTE; HUMAN; MALE; MOUSE; MUTATION; RNA INTERFERENCE;

ANIMALS; ANTITHROMBINS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR IX; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOSTASIS; HOMOZYGOTE; HUMANS; MALE; MICE; MUTATION; RNA INTERFERENCE;

EID: 84937764228     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3847     Document Type: Article

References (39)

1. Escuriola Ettingshausen, C. et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb. Haemost. 85, 218-220 (2001).
2. Franchini, M. & Lippi, G. Factor V Leiden and hemophilia. Thromb. Res. 125, 119-123 (2010).
3. Franchini, M. et al. Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia. Semin. Thromb. Hemost. 35, 307-312 (2009).
4. Ghosh, K., Shetty, S. & Mohanty, D. Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay. Haemophilia 7, 9-12 (2001).
5. Kurnik, K. et al. Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children-results of a multicenter study. Haematologica 92, 982-985 (2007).
6. Lee, D.H. et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb. Haemost. 83, 387-391 (2000).
7. Negrier, C., Berruyer, M., Durin, A., Philippe, N. & Dechavanne, M. Increased thrombin generation in a child with a combined factor IX and protein C deficiency. Blood 81, 690-695 (1993).
8. Shetty, S. et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br. J. Haematol. 138, 541-544 (2007).
9. Tizzano, E.F., Cornet, M., Domenech, M. & Baiget, M. Modifier genes in haemophilia: Their expansion in the human genome. Haemophilia 8, 250-254 (2002).
10. Bertina, R.M. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369, 64-67 (1994).
11. Langlois, N.J. & Wells, P.S. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review. Thromb. Haemost. 90, 17-26 (2003).
12. Rees, D.C., Cox, M. & Clegg, J.B. World distribution of factor V Leiden. Lancet 346, 1133-1134 (1995).
13. Bucciarelli, P. et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler. Thromb. Vasc. Biol. 19, 1026-1033 (1999).
14. Patnaik, M.M. & Moll, S. Inherited antithrombin deficiency: a review. Haemophilia 14, 1229-1239 (2008).
15. Bolliger, D., Szlam, F., Suzuki, N., Matsushita, T. & Tanaka, K.A. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice. Thromb. Haemost. 103, 1233-1238 (2010).
16. Di Micco, B. et al. Inhibition of antithrombin by protein SV-IV normalizes the coagulation of hemophilic blood. Eur. J. Pharmacol. 391, 1-9 (2000).
17. Beltrán-Miranda, C.P., Khan, A., Jaloma-Cruz, A.R. & Laffan, M.A. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 11, 326-334 (2005).
18. Dargaud, Y. et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb. Haemost. 93, 475-480 (2005).
19. Santagostino, E. et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J. Thromb. Haemost. 8, 737-743 (2010).
20. van Boven, H.H., Vandenbroucke, J.P., Briët, E. & Rosendaal, F.R. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. Blood 94, 2590-2594 (1999).
21. de Fougerolles, A., Vornlocher, H.P., Maraganore, J. & Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6, 443-453 (2007).
22. Novina, C.D. & Sharp, P.A. The RNAi revolution. Nature 430, 161-164 (2004).
23. Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819-829 (2013).
24. Fitzgerald, K. et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383, 60-68 (2014).
25. Tabernero, J. et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3, 406-417 (2013).
26. Nair, J.K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958-16961 (2014).
27. Bi, L. et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat. Genet. 10, 119-121 (1995).
28. Falati, S., Gross, P., Merrill-Skoloff, G., Furie, B.C. & Furie, B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat. Med. 8, 1175-1181 (2002).
29. Ivanciu, L. et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat. Biotechnol. 29, 1028-1033 (2011).
30. Schlachterman, A. et al. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J. Thromb. Haemost. 3, 2730-2737 (2005).
31. Peng, A., Straubinger, R.M. & Balu-Iyer, S.V. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J. 12, 473-481 (2010).
32. Pastoft, A.E. et al. A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate((R))). Haemophilia 18, 782-788 (2012).
33. Pastoft, A.E., Ezban, M., Tranholm, M., Lykkesfeldt, J. & Lauritzen, B. Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model. Haemophilia 19, 913-919 (2013).
34. Buyue, Y., Whinna, H.C. & Sheehan, J.P. The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis. Blood 112, 3234-3241 (2008).
35. Feng, D., Whinna, H., Monroe, D. & Stafford, D.W. FVIIa as used pharmacologically is not TF dependent in hemophilia B mice. Blood 123, 1764-1766 (2014).
36. Landesman, Y. et al. In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR). Silence 1, 16 (2010).
37. Hui, K.Y., Haber, E. & Matsueda, G.R. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 222, 1129-1132 (1983).
38. Weiler-Guettler, H. et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J. Clin. Invest. 101, 1983-1991 (1998).
39. Hemker, H.C. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol. Haemost. Thromb. 33, 4-15 (2003).